FDA approves 1st-of-its-kind breast cancer treatment

The FDA has granted accelerated approval to Etcamah (camizestrant), the first cancer therapy approved based on detection of a resistance mutation in circulating tumor DNA prior to visible disease progression. The treatment targets HR-positive, HER2-negative breast cancer patients with an ESR1 mutation detected during aromatase inhibitor and CDK4/6 inhibitor therapy, improving progression-free survival compared to standard care.

This Wire brief sits within Fusion42's coverage of Biotech, and 14 sources have reported it between 4 Sep 2026 and 9 Sep 2026.